Click Therapeutics

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Click Therapeutics sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).

15 total trials none currently recruiting 15 completed later-stage tilt top decile by trial count

Click Therapeutics: 15 sponsored US clinical trials, none currently recruiting.

Click Therapeutics sponsors 15 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 15 completed. 3 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Headache, Migraine, with 2 trials.

Top-decile sponsor footprint

Click Therapeutics ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

15 of 15 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

15 total, page 1 of 1

COMPLETED NA

An Exploratory, Double-arm, 8-week Study to Explore the Feasibility and Acceptability of Abbreviated Treatment with CT-156 in People with Schizophrenia.

NCT06486948

COMPLETED NA

An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis

NCT06275659

COMPLETED NA

An Exploratory Study to Evaluate Attention Biases in Adults With Multiple Sclerosis, Breast Cancer, and Lung Cancer

NCT06136923

COMPLETED NA

A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia

NCT06136936

COMPLETED Phase 3

An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia

NCT06067984

COMPLETED Phase 3

Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)

NCT06004388

COMPLETED Phase 3

Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia

NCT05838625

COMPLETED NA

Study of Two Digital Therapeutics for the Prevention of Episodic Migraine

NCT05853900

COMPLETED NA

Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training

NCT05573685

COMPLETED NA

7-week Study With CT-155 in People With Schizophrenia

NCT05486312

COMPLETED NA

Effects of a CT-100 DiNaMo Component on Cognitive Functioning and Mood Symptoms

NCT05438147

COMPLETED NA

Exploratory Study of a Digital Therapeutics in People With Schizophrenia

NCT05438160

COMPLETED

Clinical Learning Study for a Mobile Smoking Cessation Program

NCT04857515

COMPLETED NA

Ecological Momentary Assessment and Text Message Intervention for Stress Management

NCT04907942

COMPLETED NA

Clinical Trial of Smoking Cessation Mobile Phone Program

NCT02656745

How the Click Therapeutics archive is shaped

15 indexed studies, none listed as recruiting (0% open); 15 completed (100%).

Phase mix: 3 late (III/IV) vs 0 early (I/II) (later-stage heavy).

Top condition: Headache, Migraine (2 trials), 8 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Click Therapeutics: archived-pipeline peers nationwide

Peers matched on 15 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Click Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05101520 0%10%20%30%40% Total trials Recruiting share Click TherapeuticsAllakosArbor Research Collaborative for HealthArena PharmaceuticalsArrowhead Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Click Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Click Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 15 archived trials

Sponsors with similar archive density (± trial count)

What to do with this Click Therapeutics page

15 registered trials is a research-attention snapshot, not an endorsement of Click Therapeutics or any single study.

  • None of Click Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Headache, Migraine is the condition Click Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Headache, Migraine trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Click Therapeutics pipeline card: 15 registered trials from official public datasets.Report a data error.